Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi Consensus
Abstract Introduction Several systemic therapies have been approved for the treatment of severe AD. In particular, Janus kinase inhibitors (JAKi), including abrocitinib, baricitinib, and upadacitinib, recently received approval for the treatment of patients with severe AD after being evaluated in se...
Kaydedildi:
Asıl Yazarlar: | , , , , , , , , , , , , , |
---|---|
Materyal Türü: | Kitap |
Baskı/Yayın Bilgisi: |
Adis, Springer Healthcare,
2024-03-01T00:00:00Z.
|
Konular: | |
Online Erişim: | Connect to this object online. |
Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|
Internet
Connect to this object online.3rd Floor Main Library
Yer Numarası: |
A1234.567 |
---|---|
Kopya Bilgisi 1 | Kütüphanede |